<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>259-HALOTHANE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HALOTHANE" rxcui="5095">
<ATC code="N01AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS" code="R03C-001" /></DRUG2>
<DESCRIPTION>In cases of obstetrical surgery, increased uterine inertia with risk of hemorrhage; furthermore serious ventricular arrhythmias, due to increase of the cardiac reactivity</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Interrupt treatment with the beta-2 agonist if the anesthesia must be done with halothane</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>259-HALOTHANE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HALOTHANE" rxcui="5095">
<ATC code="N01AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increase of cardiac sensitization</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
